Nuvectis Pharma has entered into an exclusive licensing agreement with Haisco Pharmaceutical Group for the ex-China rights to two clinical-stage small-molecule candidates, expanding its portfolio in complement-mediated diseases and oncology.

Under the agreement, Nuvectis will obtain global exclusive rights to both assets, while Haisco will retain rights to NXP100 in India and certain Southeast Asian territories. Haisco is eligible to receive up to US$40 million in upfront and near-term payments, up to US$1.421 billion in development, regulatory, and commercial milestones, plus tiered royalties on future net sales.

The deal covers NXP100 / HSK39297, a once-daily oral Factor B inhibitor for complement-mediated diseases, and NXP200 / HSK42360, a next-generation paradox breaker BRAF inhibitor for oncology.

NXP100 is being developed for paroxysmal nocturnal hemoglobinuria (PNH) and IgA nephropathy (IgAN). In China, two marketing authorization applications for PNH have been submitted to the NMPA and are currently under review, supported by positive Phase III data. The asset is also being evaluated in a Phase III study for IgAN following positive Phase II results.

NXP200 is designed to address limitations of earlier BRAF inhibitors, including paradoxical MAPK pathway activation and acquired resistance. Clinical data to date suggest single-agent activity in CNS tumors and other BRAF-mutant solid tumors, including gliomas, NSCLC, colorectal cancer, and papillary thyroid cancer. The program is currently in Phase Ib development in China.

The transaction further strengthens Haisco’s global BD momentum and highlights the rising international value of China-originated small-molecule innovation with differentiated mechanisms, clinical validation, and global market potential.